This Community is Archived.

This community is no longer active as of December 2018. Thanks to those who posted here and made this information available to others visiting the site.

Just released: ACCISS Study in The Lancet Diabetes & Endocrinology

By Eric Obscherning Moderator | 11 Feb, 2016

On February 9, Health Action InternationaI (HAI) published a report entitled 'Access to insulin: current challenges and constraints' and The Lancet Diabetes & Endocrinology published a companion review 'Constraints and challenges in access to insulin: a global perspective

The underlining message in the report and review is that insulin remains out of reach for approximately half of those who need it.

While, as David Beran (lead author) is the first to admit, 'Insulin access is a complex challenge', there are clear issues that affect access to insulin. These include the global insulin market being dominated by three multinational manufacturers, import duties affecting the price of insulin entering different countries, and mark- ups, taxes and other costs in the pharmaceutical supply chain impacting patient prices in the public and private sectors.

Attached resources:

Replies

 

Milan Gautam Replied at 8:23 AM, 13 Feb 2016

Thank you!

This Community is Archived.

This community is no longer active as of December 2018. Thanks to those who posted here and made this information available to others visiting the site.